The Hook: A Supplement That Worked Only Where It Was Needed
Vaccines often underperform in people over 65. A new Oxford-led pilot trial suggests that a polyamine found in wheat germ, aged cheese and soy, spermidine, may help in exactly the cases where the shot fell flat. The catch is that the benefit appeared only in people who didn't respond to the vaccine in the first place.
The study was published in Aging Cell in 2026. It is small, early and partly linked to supplement-industry consultants. It is also one of the more mechanistically detailed human data sets on an "autophagy supplement" to date.
The Study Design
- Design: double-blind, randomised, placebo-controlled pilot study
- Participants: 40 healthy adults over 65
- Context: enrolled after their third SARS-CoV-2 vaccine dose
- Intervention: 6 mg/day spermidine, taken orally for 13 weeks, versus placebo
- Primary aims: safety, plus effects on vaccine-induced immunity
Supplementation was well tolerated. The researchers were based at the University of Oxford, the Max-Delbrück Center in Berlin, the University of Graz and Cardiff University.
Why Vaccines Fail Older Adults
Older immune systems respond to vaccines less vigorously. The authors point to weaker B and T cell memory responses, driven by impaired autophagy (the cell's recycling system), immunosenescence and chronic low-grade inflammation.
Spermidine has induced autophagy and counteracted immunosenescence in preclinical models, and its levels decline with age in humans. That made it a logical candidate to test in an older vaccinated population.
Finding #1: Non-Responders Had a Distinct "Senescence Signature"
Vaccine non-responsiveness was common in this cohort. The non-responders also looked different at the cellular level. Their lymphocytes showed:
- elevated p16, a classic senescence marker
- heightened mTOR signalling
- γ-H2AX+ DNA damage
The authors suggest these markers could eventually help predict vaccine failure in ageing populations. That idea needs testing in larger cohorts.
Finding #2: Spermidine Reversed the Signature and Boosted Immunity
In non-responders, spermidine reversed these senescence features. It also significantly enhanced:
- spike-specific IgG secretion
- memory B cell recall responses
- neutralising antibody activity
The key phrase in the paper is "specifically in non-responders." The abstract reports no comparable boost in people who already responded well. The data do not show spermidine acting as a general immune booster.
Finding #3: The Autophagy Fingerprint
Single-cell RNA sequencing after treatment showed increased expression of TFEB targets and autophagy-related genes in B cells. TFEB is a master regulator of lysosomal and autophagy programmes. This is consistent with elevated autophagic flux, so the immune benefit appears to match the proposed mechanism rather than just a change in antibody numbers.
The Contrast: Spermidine's Memory Disappointment
Spermidine's human record has not been uniformly strong. The earlier SmartAge trial tested a low dose, 0.9 mg/day, for cognitive benefit in older adults with subjective memory decline. It did not show a clear memory improvement over placebo.
The two trials aren't directly comparable. The outcomes (memory versus vaccine immunity), populations and durations all differ. The dose is also roughly 6.7 times higher here (6 mg versus 0.9 mg). Whether dose explains the different results is a hypothesis, not a conclusion. A more modest reading is that spermidine may work better in a targeted, biologically defined setting, such as immune cells showing senescence markers, than as a broad "healthy ageing" pill.
What This Means for You
Dose studied: 6 mg/day, taken orally. The trial did not test other doses, so there is no basis for assuming more is better.
Duration: 13 weeks, following a third COVID-19 vaccine dose. The abstract does not describe exact timing relative to vaccination beyond that, so don't treat it as a validated schedule.
Who it might be relevant to: adults over 65 who are generally healthy and who have a history of poor vaccine responses. However, the benefit was seen in non-responders, and the study didn't establish a clinical test for identifying them. Antibody testing after vaccination, arranged through a clinician, is the most practical way to know your status.
- People who responded well to their vaccines. No benefit was shown for them.
- Immunocompromised people, transplant recipients, or anyone on immunosuppressive drugs. The trial enrolled healthy adults, so these groups are untested.
- Anyone with significant medical conditions or on multiple medications should talk to a doctor first.
- Anyone hoping spermidine will replace boosters or standard medical advice. It won't.
Caveats You Should Not Skip
- Pilot size: 40 participants is small. Once split into responders and non-responders, the subgroups are smaller still, and the findings are hypothesis-generating.
- Single vaccine context: all participants had SARS-CoV-2 vaccination. Results may not carry over to flu, shingles or pneumococcal vaccines.
- Antibody and cellular markers, not clinical outcomes: the study measured immune responses, not whether fewer people got sick.
- Duration: 13 weeks says nothing about long-term effects.
- Conflicts of interest: some authors consult for The Longevity Labs and Oxford Healthspan, both spermidine-related companies. The disclosure states that TLL had no input into trial design, results, analysis or the manuscript.
The Bottom Line
This trial doesn't prove that spermidine is a vaccine enhancer. It does offer a coherent, biologically grounded signal: in older adults who responded poorly to a third dose, 6 mg/day for 13 weeks reversed senescence-linked features and improved antibody and memory B cell readouts, with autophagy-related gene changes to match. A larger, multi-vaccine, clinically oriented trial is the necessary next step. Until then, spermidine is a promising research lead rather than a proven fix.
